First Department of Dermatology and Venereology, School of Medicine, Aristotle University, Thessaloniki, Greece.
Clin Exp Dermatol. 2021 Dec;46(8):1542-1544. doi: 10.1111/ced.14665. Epub 2021 May 11.
Apremilast has been approved as an effective and safe treatment for psoriasis, but clinical trial results may differ from real-life data. This retrospective cross-sectional study evaluated the long-term efficacy and safety of apremilast in a Greek cohort of adult patients with psoriasis who had received at least one dose of apremilast between March 2016 and January 2021. The primary endpoint was the percentage of patients who achieved 75% reduction in Psoriasis Area Severity Index (PASI75) at Week 16. Absolute PASI, PASI90 (90% reduction) and adverse events were also recorded at various timepoints. In total, 102 patients (29.4% women, 70.6% men) with a mean ± SD age 55.94 ± 15.21 years were included. PASI75 and PASI90 were achieved by 20.8% and 1.98% of patients, respectively, at Week 16. According to our results, PASI90 achievement was significantly lower than that reported in clinical trials. The efficacy of apremilast increased gradually until Week 24, with further improvement noted in good responders up to Week 52.
阿普司特已被批准为治疗银屑病的有效且安全的药物，但临床试验结果可能与真实世界的数据有所不同。本回顾性横断面研究评估了阿普司特在希腊成年银屑病患者队列中的长期疗效和安全性，这些患者在 2016 年 3 月至 2021 年 1 月期间至少接受过一次阿普司特治疗。主要终点是第 16 周时达到银屑病面积严重程度指数（PASI75）改善 75%的患者比例。还记录了在不同时间点的绝对 PASI、PASI90（90%改善）和不良反应。共纳入 102 例患者（29.4%女性，70.6%男性），平均年龄为 55.94±15.21 岁。第 16 周时，分别有 20.8%和 1.98%的患者达到 PASI75 和 PASI90。根据我们的结果，PASI90 的达标率显著低于临床试验报道的水平。阿普司特的疗效逐渐增加，直到第 24 周，在治疗反应良好的患者中，直至第 52 周时仍有进一步改善。
